CXCL17: A Potential Drug Target for Immune and Angiogenesis (G284340)

Target Name: CXCL17

NCBI ID: G284340

CXCL17

CXCL17: A Potential Drug Target for Immune and Angiogenesis

CXCL17 (VEGF co-regulated chemokine 1) is a protein that is expressed in various tissues throughout the body, including the skin, hair, and eyes. It is a member of the chemokine family, which are a group of small proteins that are involved in the recruitment of immune cells to sites of infection or inflammation.

One of the functions of CXCL17 is to regulate the movement of immune cells to the site of an infection or inflammation. This is accomplished through its ability to interact with integrins, which are a type of protein that is found on the surface of immune cells. Integrins are responsible for adhering cells to various tissues and organs, including the skin and blood vessels.

CXCL17 plays a key role in the regulation of skin inflammation, as it is able to attract and retain immune cells that are involved in the immune response. This is important for protecting the skin from the harmful effects of pathogens and other irritants.

In addition to its role in immune regulation, CXCL17 has also been shown to have potential as a drug target. The ability of CXCL17 to interact with integrins makes it a potential target for drugs that are designed to inhibit the activity of integrins. This could be useful for treating a variety of conditions, including cancer, autoimmune diseases, and wound infections.

Another potential use for CXCL17 as a drug target is its role in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. CXCL17 has been shown to play a key role in the regulation of angiogenesis, and it is possible that it could be used to treat a variety of conditions that are characterized by the build-up of excess blood vessels.

In addition to its potential as a drug target, CXCL17 also has important functions in the regulation of cell signaling pathways. It is a member of the TGF-β pathway, which is a well-established pathway that is involved in the regulation of cell growth, differentiation, and inflammation.

CXCL17 has also been shown to play a key role in the regulation of the immune response. It is a signaling molecule that is involved in the recruitment of T cells, which are a type of immune cell that play a critical role in the immune response.

Overall, CXCL17 is a protein that has important functions in the regulation of various biological processes in the body. Its ability to interact with integrins and its potential as a drug target make it an attractive target for research into the treatment of a variety of conditions. Further research is needed to fully understand the role of CXCL17 in the immune system and its potential as a drug.

Protein Name: C-X-C Motif Chemokine Ligand 17

Functions: Chemokine that acts as chemoattractant for monocytes, macrophages and dendritic cells (PubMed:16455961, PubMed:23115081). Plays a role in angiogenesis and possibly in the development of tumors (PubMed:16989774, PubMed:23115081). Acts as an anti-inflammatory in the stomach (PubMed:23115081). May play a role in the innate defense against infections (PubMed:17307946). Activates the C-X-C chemokine receptor GPR35 to induce a rapid and transient rise in the level of intracellular calcium ions (PubMed:25411203)

The "CXCL17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CXCL17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets